Related Experiment Videos
Diagnosis and management of gastrointestinal neuroendocrine tumors
I M Modlin1, M D Basson, S Mani
1Department of Surgery, Yale University School of Medicine, New Haven, CT 06510.
Abstract:
Neuroendocrine tumors of the gastrointestinal tract pose substantial diagnostic and therapeutic challenges. The numerous biologically active peptides and amines produced by these lesions generate complex clinical syndromes. Unfortunately, little is known regarding the genesis of these lesions. Recent advances in understanding of the pathobiology of these lesions has facilitated characterization of the biochemistry of tumor secretions. Similarly, pharmacological blockade of tumor bioactivity using somatostatin analogs, pharmacotherapeutic probes, or specific antagonists has enhanced treatment options. Effective biochemical palliation of tumor symptoms has in turn motivated a more aggressive approach to cytoreduction of these tumors by surgery or hepatic embolization. The combination of chemical blockade and surgical therapy may permit more extended and symptom-free survival for a significant proportion of patients. We evaluate the basic principles of diagnosis and management of gastrointestinal neuroendocrine tumors.
Insights
Gastrointestinal neuroendocrine tumors present diagnostic and therapeutic challenges due to complex syndromes. Advances in understanding tumor biochemistry and targeted therapies improve patient survival.
Area of Science:
- Gastroenterology
- Endocrinology
- Oncology
Background:
- Gastrointestinal neuroendocrine tumors (GI-NETs) present complex diagnostic and therapeutic challenges.
- Tumor secretions of biologically active peptides and amines cause intricate clinical syndromes.
- The precise genesis of GI-NETs remains incompletely understood.
Purpose of the Study:
- To evaluate the fundamental principles of diagnosis and management for GI-NETs.
- To highlight recent advances in understanding GI-NET pathobiology and biochemistry.
- To discuss current therapeutic strategies for symptom management and tumor control.
Main Methods:
- Review of current literature on GI-NET diagnosis and management.
- Characterization of tumor secretions and their biochemical properties.
- Evaluation of pharmacological blockade strategies including somatostatin analogs and antagonists.
- Assessment of cytoreductive therapies such as surgery and hepatic embolization.
Main Results:
- Advances in pathobiology have improved characterization of tumor secretions.
- Pharmacological blockade offers enhanced treatment options for tumor bioactivity.
- Effective biochemical palliation supports more aggressive cytoreductive approaches.
- Combination therapy may lead to extended, symptom-free survival.
Conclusions:
- Integrated management combining chemical blockade and cytoreductive therapies offers improved outcomes for GI-NET patients.
- Further research into GI-NET genesis is warranted.
- Optimized diagnosis and management are crucial for enhancing patient survival and quality of life.